Company / Return on Equity (ROE)
Biogen Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
7.1%
FY2025
5-year range
7.1% / 22.7%
FY2021-FY2025
Trend
-27.5%
vs FY2024
Sector context
#40 of 190
Health Care
What the data says
Biogen's return on equity (roe) of 7.1% is higher than 79% of companies in the Health Care sector (FY2025). Return on Equity (ROE) has fluctuated over the past 10 years, ranging from 7.1% in FY2025 to 44.1% in FY2019.
Based on SEC 10-K filings.
7.1% in FY2025 with a 5-year CAGR of -30.3%. Top quartile in the Health Care sector.
Declined from 7.8% to 7.1% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -15.7pp
- 5-Year Change
- -30.3pp
- 10-Year Change
- -
Sector benchmark
+114.1% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 27.5% year-over-year.
- Currently 57.3pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2019.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 7.1% | -27.5% |
| FY2024 | 9.8% | +24.3% |
| FY2023 | 7.8% | -65.5% |
| FY2022 | 22.7% | +59.2% |
| FY2021 | 14.3% | -61.8% |
| FY2020 | 37.4% | -15.3% |
| FY2019 | 44.1% | +29.9% |
| FY2018 | 34.0% | +68.8% |
| FY2017 | 20.1% | -34.0% |
| FY2016 | 30.5% | -19.4% |
As of FY2025 · SEC 10-K · Updated Mar 3, 2026